SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events

Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Cloquet, Maarten Schram, Rutger Scharloo, Tim Boersma, Tim Stobernack, Pieter van Gelder
doi: https://doi.org/10.1101/2022.01.10.21268254

Article Information

doi 
https://doi.org/10.1101/2022.01.10.21268254
History 
  • February 15, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Bas Kolen1,2,*,
  2. Laurens Znidarsic1,
  3. Andreas Voss3,4,
  4. Simon Donders5,
  5. Iris Kamphorst5,
  6. Maarten van Rijn5,
  7. Dimitri Bonthuis6,
  8. Merit Cloquet6,
  9. Maarten Schram6,
  10. Rutger Scharloo6,
  11. Tim Boersma6,
  12. Tim Stobernack3 and
  13. Pieter van Gelder1
  1. 1Delft University of Technology, Delft, The Netherlands
  2. 2HKV lijn in water, Lelystad, The Netherlands
  3. 3Radboudumc, Nijmegen, The Netherlands
  4. 4Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
  5. 5Breda University of Applied Sciences, Breda, The Netherlands
  6. 6Fieldlab Program Committee, Zaandam, The Netherlands
  1. ↵*Corresponding author:
    Bas Kolen, Address for correspondence: Bas Kolen, HKV Consultants, Botter 11-29, 8203 AC Lelystad, the Netherlands; email: b.kolen{at}hkv.nl
Back to top
Posted February 15, 2022.
Download PDF
Data/Code
Email
SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Cloquet, Maarten Schram, Rutger Scharloo, Tim Boersma, Tim Stobernack, Pieter van Gelder
medRxiv 2022.01.10.21268254; doi: https://doi.org/10.1101/2022.01.10.21268254
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area